(Adds analyst, detail)
OSLO Dec 19 Denmark's Novo Nordisk
has ended its testing programme for a drug to treat bowel
disorder Crohn's disease after an unsuccessful phase 2a trial.
The analysis on the active substance, called anti-NKG2D, did
not meet the pre-specified criteria for effect, the company said
It also said that it had completed a phase 3a programme for
IDegLira, a combination of its insulin drugs Tresiba and
Victoza, and that it would go ahead with a bigger study by the
end of next year.
"The trials show that patients can realise benefits from
each of the components in the combination product," Novo Nordisk
said, adding that it planned for regulatory filing for IDegLira
in the EU and in the United States during 2013.
"This combination looks like it could be a very attractive
treatment opportunity for people with type II diabetes," said
Sydbank analyst Soeren Hansen.
Novo Nordisk has put its hopes on Tresiba, a new long-acting
diabetes drug pending marketing approval in Europe and the U.S.,
to reach blockbuster status with annual sales of more than $1
(Reporting by Victoria Klesty; Editing by Louise Heavens)